SCHEMBL1697359

SCHEMBL1697359

CN(C)CC(=O)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.33
HSD11B1 P28845 1/20 0.30
KDM4E B2RXH2 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
EGFR P00533 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26382115 0.82 HSD11B1 (0.34) KMT2AHSD11B1
SCHEMBL2614240 0.78 KMT2A (0.31) KMT2A
SCHEMBL27419998 0.78 KMT2A (0.33) KMT2A
SCHEMBL10072131 0.78 KMT2A (0.31) KMT2AKDM4E
SCHEMBL13142134 0.78
SCHEMBL26508547 0.78 CA12 (0.43)
SCHEMBL31158128 0.78 DRD3 (0.37) KDM4E
SCHEMBL15498540 0.76 KMT2A (0.30) KMT2A
SCHEMBL14375590 0.76 CHRM1 (0.38) KMT2A
SCHEMBL19091682 0.76 RIPK1 (0.37) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024232563-A1 GROUP 14 ORGANOMETALLIC COMPOUND, PREPARATION METHOD THEREFOR, AND METHOD FOR FORMING THIN FILM BY USING SAME 한국화학연구원 2024-11-14 WO disclosed
US-20230348360-A1 Amino Lipid and Preparation Method and Application Thereof SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD (CN) 2023-11-02 US disclosed
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2023-10-05 US disclosed
US-20230158141-A1 Conjugates of Biomolecule and Use Thereof YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) 2023-05-25 US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 US disclosed
US-20230043863-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2023-02-09 US disclosed
US-10882883-B2 Derivatives of amphotericin B SFUNGA THERAPEUTICS, INC. (US) 2021-01-05 US disclosed
US-20200262858-A1 DERIVATIVES OF AMPHOTERICIN B ELION THERAPEUTICS, INC. 2020-08-20 US disclosed
US-10669252-B2 Benzazepine derivative, preparation method, pharmaceutical composition and use thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2020-06-02 US disclosed
US-20190276489-A1 PROGESTERONE ANALOGS AND USES RELATED THERETO EMORY UNIVERSITY 2019-09-12 US disclosed
US-20080045496-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 US disclosed
US-20080027100-A1 Functionally selective alpha2C adrenoreceptor agonists SCHERING CORPORATION AND PHARMACOPEIA, INC. 2008-01-31 US disclosed
US-7312359-B2 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders ROCHE PALO ALTO LLC (US) 2007-12-25 US disclosed
US-20070293526-A1 Arylsulfonyl naphthalene derivatives and uses thereof ROCHE PALO ALTO LLC 2007-12-20 US disclosed
US-20070244055-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F 2007-10-18 US disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-20070129309-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F 2007-06-07 US disclosed
US-20070099872-A1 Functionally selective alpha2C adrenoreceptor agonists SCHERING CORPORATION 2007-05-03 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20070021350-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348360-A1 Amino Lipid and Preparation Method and Application Thereof SLC7A1, SLC7A5, SLC43A1 KMT2A 1095/4885HSD11B1 4172/4885KDM4E 643/4885
US-20070293526-A1 Arylsulfonyl naphthalene derivatives and uses thereof ARSA, AR, SULT2A1 KMT2A 879/4885HSD11B1 976/4885KDM4E 1655/4885
US-20230158141-A1 Conjugates of Biomolecule and Use Thereof CD47, FCGR2A, CD40 KMT2A 2284/4885HSD11B1 4492/4885KDM4E 2983/4885
US-10882883-B2 Derivatives of amphotericin B C9, ERG28, AMPD3 KMT2A 4170/4885HSD11B1 2063/4885KDM4E 2646/4885
US-10669252-B2 Benzazepine derivative, preparation method, pharmaceutical composition and use thereof TLR8, TLR1, TLR5 KMT2A 751/4885HSD11B1 1367/4885KDM4E 1342/4885
US-20070129309-A1 Conjugates useful in the treatment of prostate cancer BPHL, KLK3, DNPEP KMT2A 154/4885HSD11B1 1469/4885KDM4E 1171/4885
US-20230043863-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF WEE2, WEE1, RORB KMT2A 2361/4885HSD11B1 91/4885KDM4E 2064/4885
US-20080027100-A1 Functionally selective alpha2C adrenoreceptor agonists ADRA2C, ADRB2, ADRA2A KMT2A 1902/4885HSD11B1 522/4885KDM4E 3667/4885
US-20070244055-A1 Conjugates useful in the treatment of prostate cancer BPHL, KLK3, DNPEP KMT2A 213/4885HSD11B1 1766/4885KDM4E 1500/4885
US-20070099872-A1 Functionally selective alpha2C adrenoreceptor agonists ADRA2C, ADRB2, ADRA2A KMT2A 1902/4885HSD11B1 522/4885KDM4E 3667/4885
US-20200262858-A1 DERIVATIVES OF AMPHOTERICIN B C9, ERG28, AMPD3 KMT2A 4170/4885HSD11B1 2063/4885KDM4E 2646/4885
US-20190276489-A1 PROGESTERONE ANALOGS AND USES RELATED THERETO PGR, SHBG, PGRMC1 KMT2A 3136/4885HSD11B1 144/4885KDM4E 2553/4885
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A KMT2A 1591/4885HSD11B1 2081/4885KDM4E 2689/4885
US-20070021350-A1 Conjugates useful in the treatment of prostate cancer BPHL, KLK3, DNPEP KMT2A 213/4885HSD11B1 1766/4885KDM4E 1500/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KMT2A 1305/4885HSD11B1 4731/4885KDM4E 1041/4885
US-20080045496-A1 PYRROLOTRIAZINE KINASE INHIBITORS JAK2, NTRK2, NTRK3 KMT2A 1500/4885HSD11B1 3510/4885KDM4E 1939/4885
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 KMT2A 4174/4885HSD11B1 2587/4885KDM4E 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.